PHR - Phreesia, Inc.

Phreesia provides its Phreesia platform, a patient intake and engagement software suite used by healthcare organizations to digitize registration, insurance verification, consent, and payments at the point of care. The business model is B2B SaaS sold to physician practices, health systems, and hospitals in the United States, with revenue from platform subscription fees plus payment processing volume. Phreesia generates approximately $400M in annual revenue, operating almost exclusively in the U.S. healthcare market. The company serves over 4,000 healthcare clients and processes patient intake for tens of millions of patient visits annually.

Past Year Trends

• Phreesia achieved its first-ever positive GAAP net income in Q2 FY2026 (quarter ended July 31, 2025) at $700K, then delivered full-year GAAP net income of $2.3M for FY2026 (ended January 31, 2026), crossing $100M Adjusted EBITDA and $50M free cash flow in the same year. (Bullish)
• Total revenue for FY2026 grew approximately 14-15% year-over-year, with Q4 FY2026 reaching $127.1M (up 16% YoY) and full-year revenue tracking toward ~$480M, driven by network solutions segment growth of 29% in FY2025 and continued double-digit gains in FY2026. (Bullish)
• Phreesia slashed its FY2027 revenue guidance by approximately $37M at the midpoint (from $545-$559M down to $510-$520M) in March 2026, citing pharmaceutical manufacturer clients committing lower network solutions spend due to brand-specific dynamics and regulatory policy impacts, sending the stock down roughly 29% and triggering a federal securities fraud class action lawsuit. (Bearish)

Next Year Trends

• Pharma manufacturer network solutions spending uncertainty is the primary near-term headwind: Phreesia disclosed reduced visibility into second-half FY2027 commitments from drug-brand clients due to regulatory policy impacts, with revenue-per-AHSC expected to grow only in the low single digits in FY2027 versus double-digit growth in prior years. (Bearish)
• A federal securities fraud class action lawsuit (filed April 2026, led by Levi & Korsinsky) alleging misleading revenue guidance represents a litigation overhang that could consume management attention and result in material settlement costs over the next 12 months. (Bearish)
• Average healthcare services client (AHSC) count reached 4,520 as of Q3 FY2026 (up 7% YoY), and Phreesia's AccessOne payment plan platform provides a subscription revenue base that is insulated from pharma spend volatility, offering a partial offset to network solutions weakness if AHSC adds continue. (Neutral)

Red Flags

(b) Securities fraud class action lawsuit — Multiple law firms (Schall Law Firm, Pomerantz Law Firm, Kirby McInerney LLP, Robbins LLP, Rosen Law Firm, Gross Law Firm) filed federal securities class action lawsuits against Phreesia, Inc. and named executives in May 2026, alleging that defendants made materially false and misleading statements between May 8, 2025 and March 30, 2026 regarding the durability of the Network Solutions segment and fiscal year 2027 revenue guidance, concealing weakening pharmaceutical marketing commitments and reduced visibility into future spending, causing the stock to drop approximately 27% when the guidance cut was disclosed on March 30, 2026; source: GlobeNewswire / PRNewswire / BusinessWire, May 2026.